Release Date: January 23, 2017
Expiration Date: January 23, 2018
Media: Print with online posttest, evaluation, and request for credit
Overview
This activity is designed to inform physicians about current and emerging treatment approaches in patients with glioblastoma.
Instructions for Participation/How to Receive Credit:
|
Target Audience
This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with glioblastoma. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other healthcare providers are also invited to participate.
Learning Objectives
After participating in this CME/CE activity, learners should be better prepared to
- Discuss the challenges associated with effective drug delivery to patients with glioblastoma
- Summarize the main findings of studies investigating the prognostic and predictive value of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in patients with glioblastoma
- Characterize the technology currently used to identify MGMT promoter methylation status in patients with glioblastoma
- State the contributions of The Cancer Genome Atlas (TCGA) researchers to the genomic understanding of glioblastoma
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
Faculty
David A. Reardon, MD
Clinical Director, Center for Neuro-Oncology Physician
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Disclosure: Grant/Research Support - Celldex; Incyte; Midatech. Consultant - Abbvie; Amgen; BMS; Cavion; Genentech/Roche; Merck; Midatech; Momenta Pharmaceuticals; Novartis; Novocure; Regeneron; Stemline Therapeutics. Speaker’s Bureau- Merck; Genentech/Roche
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians’ Education Resource®, LLC (PER®), and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Target Audience
This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with glioblastoma. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other healthcare providers are also invited to participate.
Learning Objectives
After participating in this CME/CE activity, learners should be better prepared to:
- Discuss the challenges associated with effective drug delivery to patients with glioblastoma
- Summarize the main findings of studies investigating the prognostic and predictive value of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in patients with glioblastoma • Characterize the technology currently used to identify MGMT promoter methylation status in patients with glioblastoma
- State the contributions of The Cancer Genome Atlas (TCGA) researchers to the genomic understanding of glioblastoma
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.
This activity is funded by PER®
Off-Label Disclosure and Disclaimer
This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.
Disclaimer
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC.
Contact information for questions about the activity:
Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Phone: (888) 949-0045
E-mail: [email protected]
